LOGO.jpg
Interpace Announces Extension of LabCorp Agreement
February 24, 2020 06:55 ET | Interpace Biosciences, Inc.
 ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its...
17_OmniSeq_CorporateLogo_RGB.png
OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
April 23, 2019 08:00 ET | OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
IDXG Logo.jpg
Interpace Diagnostics Announces Further Expansion of Thyroid Business
January 22, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Interpace Only Provider Validated to Offer MDx Tests on Three Distinct Platforms PARSIPPANY, NJ, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it...
Laboratory Economics Issues Research Report on U.S. Clinical Laboratory Testing Market
August 14, 2018 08:00 ET | Laboratory Economics
POUGHKEEPSIE, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Get ready for some major market challenges ahead in the $97 billion U.S. lab industry according to a new research report, "The U.S. Clinical...
17_OmniSeq_CorporateLogo_RGB.png
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
July 31, 2018 16:05 ET | OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
17_OmniSeq_CorporateLogo_RGB.png
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
June 01, 2018 16:11 ET | OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
17_OmniSeq_CorporateLogo_RGB.png
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
April 12, 2018 09:00 ET | OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
Cority Enhances Clinical Testing Solution with LabCorp Interface
November 16, 2017 08:01 ET | Cority Software Inc.
Toronto, Canada, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Cority, the most trusted Environmental, Health, Safety and Quality (EHSQ) software for assuring client success, today introduced new functionality...
17_OmniSeq_CorporateLogo_RGB.png
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
November 09, 2017 08:02 ET | OmniSeq
BUFFALO, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of Roswell Park Cancer Institute, announced today that it received accreditation by the College of...
17_OmniSeq_CorporateLogo_RGB.png
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
August 21, 2017 08:01 ET | OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...